Trial Profile
Phase I Study of Tolerance and Pharmacokinetics of TQ-B3203
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs TQ-B3203 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 01 Mar 2018 New trial record